From: Research progress on dendritic cell vaccines in cancer immunotherapy
DC subtype | Morphology | Locations found in vivo | Main distinguishing surface markers detected by flow cytometry | Pattern recognition receptors | Main functions | ||
---|---|---|---|---|---|---|---|
Mouse | Human | Mouse | Human | ||||
pDC | Plasma cell-like | Lymphoid tissues and peripheral blood, lung (mouse) and tonsil (human) | CD11clow, MHC-IIlow, B220+, CD317+, SIGLEC-H+, CD172a+, CD209+, CCR2low, CCR9+, CXCR3 | CD11c−, HLA-DRlow, CD123+, D303+ (CLEC4C+), CD304+, CCR2+, CXCR3+ | TLR7, TLR9, TLR12, RLR, STING, CLEC12A | TLR7, TLR9, RLR, STING, CLEC12A | Control of viral infections, secretion of type I interferon, antigen presentation T-cell priming |
cDC1s | Irregular, stellate shape | Lymphoid tissues and peripheral blood | CD11c+, MHC-II+, CD8α+, (resident) CD103+, (migratory) CD24+, XCR1+, CLEC9A+, DEC205+ | CD11clow, HLA-DR+, CD141+a, XCR1+, CLEC9A+, DEC205+ | TLR2−, TLR4, TLR11−, TLR13, STING, CLEC12A | TLR1, TLR3, TLR6, TLR8, TLR10, STING, CLEC12A | Cellular immunity against tumor and intracellular pathogens, cross-priming |
cDC2s | Irregular, stellate shape | Lymphoid tissues and peripheral blood | CD11c+, MHC-II+, CD11b+ (high), CD172a+ | CD11c+, HLA-DR+, CD1c+a, CD11b+, CD172a+, CD1a+ (migratory), CD14, CD5 (subset) | TLR1, TLR2, TLR4−, TLR9, TLR13, RLR, NLR, STING, CLEC4A, CLEC6A, CLEC7A, CLEC12A | TLR1−, TLR9, RLR, NLR, STING, CLEC4A, CLEC6A, CLEC7A, CLEC10A, CLEC12A | CD4+ T cell priming |
MoDCs | Context dependent | Differentiate from monocytes in peripheral blood, resident in the skin, lung and intestine | CD11c+, MHC-II+, CD11b+, Ly6C+, CD64+, CD206+, CD209+, CD14+, CCR | CD11c+, HLA-DR+, CD1c+, CD11b+, CD14+, CD64+, CD206+, CD209+, CD172a+, CD1a+, CCR2+ | Not well defined | Not well defined | Generated by inflammation, CD8+ T cell priming |